Equites Radar

TLRY · Tilray Brands, Inc.

$4.03

+0.00% last session

End-of-day data · updated 2026-07-29

Bearish0 bullish · 5 bearish technical signals
Consensus: Buy (2.40 from 8 analysts)
To mean target: +124.6%

Market cap

$0B

Enterprise value

$2B

Trailing P/E

Forward P/E

15.7

Dividend yield

Beta

1.90

Avg volume

4M

Employees

3K

2D change

0.00%

5D change

3.87%

10D change

-6.28%

30D change

-12.58%

60D change

-26.86%

MTD change

-9.03%

YTD change

-55.37%

Analyst Outlook

Consensus ratingBuy
Recommendation mean (1–5)2.40
Covering analysts8
Mean price target$9.05
Low price target$5.00
Upside to mean target+124.6%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)32.8
50-day MA$4.76
200-day MA$7.97
Price vs 50-day MA-15.3%
Price vs 200-day MA-49.4%
MACD histogram-0.00
Volume vs 3-month avg1.3×
52w low $3.8852w high $21.00

Analyst sentiment over time — TLRY

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-07-14

Latest call per bank · past 12 months

Jefferies

Buy

$2.00

-50.4% vs price
▲ raised from $1.50Maintains · 2025-08-25

Recent rating actions

DateFirmActionRatingPrice target
2026-07-14TD CowenMaintainsBuy$7.00 $5.00
2026-04-02Roth CapitalUpgradeNeutralBuy$10.00
2026-03-30TD CowenMaintainsBuy$10.00 $7.00
2026-01-20Roth CapitalMaintainsNeutral$20.00 $10.00
2025-08-25JefferiesMaintainsBuy$1.50 $2.00
2025-07-29Zelman & AssocReiteratesNeutral$0.00

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-28

  • RSI (14): RSI is 33 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 15.3% below the 50-day MA ($4.76).
  • Price vs 200-day MA: Trading 49.4% below the 200-day MA ($7.97).
  • MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
  • MACD (12,26,9): MACD histogram is negative (-0.00) — short-term momentum is fading.
  • 52-week range: Price is within 10% of the 52-week low ($3.88).

TLRY Price Chart

Loading chart for TLRY

Fundamentals

Revenue (TTM)$1.0B
EBITDA$0M
Free cash flow$0M
Operating cash flow$0M
Book value / share$3.02
Net debt / EBITDA-4.6
WACC
Revenue growth-8.00%
Earnings growth

About Tilray Brands, Inc.

Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; resells and distributes pharmaceutical and wellness products; and produces, markets, and sells beverage products, and hemp-based food products. In addition, the company provides entertainment products. It offers its products under the Tilray, Aphria, Broken Coast, Symbios, Navcora, Tilray Craft, Charlotte's Web, Montauk Brewing, Shock Top, 10 Barrell, Breckenridge Brewery, SweetWater Brewing, Breckenridge Distillery, Blue Point Brewing, Broken Coast, Redecan, XMG, Manitoba Harvest, CC Pharma, Good Supply, Solei, Mollo, Chowie Wowie, Original Stash, Canaca, RIFF, Tilray Medical, Bake Sale, The Batch, HEXO, Alpine Beer Company, Green Flash, Cruisies, Atwater Brewery, Hiball Energy, Liquid Love, Hop Valley Brewing, Redhook Brewery, Revolver Brewing, Square Mile Cider, Mock One, Widmer Brothers Brewing, Runner's High Brewing Company, SweetWater Brewing Company, Terrapin Beer Co., Happy Flower, Fizzy Jane's, Herb & Bloom, 420 Fizz, and Fresh Hemp Foods brands. The company sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.

More in Drug Manufacturers - Specialty & Generic

Screen TLRY against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.